Qvt Financial LP Has Trimmed By $2.42 Million Its Sarepta Therapeutics (SRPT) Holding; Krystal Biotech (KRYS) Shorts Increased By 14.8%

February 22, 2018 - By Marie Mckinney

Krystal Biotech Inc (NASDAQ:KRYS) had an increase of 14.8% in short interest. KRYS’s SI was 34,900 shares in February as released by FINRA. Its up 14.8% from 30,400 shares previously. With 9,000 avg volume, 4 days are for Krystal Biotech Inc (NASDAQ:KRYS)’s short sellers to cover KRYS’s short positions. The SI to Krystal Biotech Inc’s float is 0.97%. The stock increased 5.54% or $0.4799 during the last trading session, reaching $9.1399. About 2,500 shares traded. Krystal Biotech, Inc. (NASDAQ:KRYS) has 0.00% since February 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Qvt Financial Lp decreased Sarepta Therapeutics Inc (SRPT) stake by 48.61% reported in 2017Q3 SEC filing. Qvt Financial Lp sold 53,863 shares as Sarepta Therapeutics Inc (SRPT)’s stock rose 22.49%. The Qvt Financial Lp holds 56,949 shares with $2.58 million value, down from 110,812 last quarter. Sarepta Therapeutics Inc now has $4.14 billion valuation. The stock increased 1.20% or $0.76 during the last trading session, reaching $63.98. About 850,391 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since February 22, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Since October 3, 2017, it had 0 insider buys, and 1 sale for $575,000 activity. Ruff Shamim also sold $575,000 worth of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Tuesday, October 3.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 81% are positive. Sarepta Therapeutics had 103 analyst reports since August 5, 2015 according to SRatingsIntel. Vetr upgraded the stock to “Buy” rating in Tuesday, August 25 report. Jefferies downgraded the stock to “Underperform” rating in Friday, April 29 report. The firm earned “Hold” rating on Wednesday, September 6 by Barclays Capital. The stock has “Buy” rating by Piper Jaffray on Thursday, October 26. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Neutral” rating by Suntrust Robinson on Friday, August 7. The firm earned “Neutral” rating on Wednesday, April 20 by Janney Capital. SunTrust downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Tuesday, April 26. SunTrust has “Reduce” rating and $4 target. The firm earned “Buy” rating on Wednesday, August 26 by TH Capital. On Tuesday, July 18 the stock rating was maintained by Cowen & Co with “Buy”. The company was maintained on Tuesday, September 20 by Needham.

Investors sentiment increased to 2.88 in Q3 2017. Its up 1.36, from 1.52 in 2017Q2. It increased, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Sigma Planning holds 0.08% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 21,350 shares. Gilder Gagnon Howe & Limited owns 534,087 shares. Susquehanna Ltd Liability Partnership holds 1.01M shares or 0.02% of its portfolio. Brighton Jones Limited Company has 0.03% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 4,661 shares. Aqr Mngmt Ltd Liability Corp holds 81,468 shares. Citadel Ltd Llc has 2.04M shares. Nationwide Fund Advsrs reported 0.01% stake. Raymond James Advsr holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 27,596 shares. Trexquant Lp owns 8,846 shares or 0.1% of their US portfolio. Stifel Fincl Corp has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Lucas Capital invested 0.22% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Balyasny Asset Mgmt Limited Liability Corporation reported 0.02% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Emerald Advisers Pa reported 893,484 shares or 1.65% of all its holdings. 5,650 were reported by Cambridge Invest Research Advisors. Pura Vida Investments Limited Liability holds 50,000 shares or 1.14% of its portfolio.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>